Traditional drug discovery mainly focuses on direct regulation of protein activity. The
development and application of protein activity modulators, particularly inhibitors, has been …

Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic
strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …

Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis
of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of …